p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression

British Journal of Cancer

Volumn 93, Issue 2, 2005, Pages 242-247

  Piaton, E ^a,b   Faynel J ^a,b   Ruffion, A ^c   Lopez, J G ^c   Perrin, P ^c   Devonec, M ^c  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Liquid based cytology; p53; Progression; Urothelial carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; BLADDER BIOPSY; BLADDER TUMOR; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNODETECTION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTANT; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CYTOLOGICAL TECHNIQUES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23644456284     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602684     Document Type: Article

References (24)

1. Anagnostopoulou I, Spathi H, Rammou-Kinnia R, Karakitsos P, Gianni I, Georgoulakis J, Kittas C (2000) Comparative study of Thinprep and conventional voided urine cytology (Abstract). Cytopathology 11: 373
2. Bastacky S, Ibrahim S, Wilczinski SP, Murphy WM (1999) The accuracy of urinary cytology in daily practice. Cancer (Cancer Cytopathol) 87: 118-128
3. Brandau S, Bohle A (2001) Bladder cancer I. Molecular and genetic basis of carcinogenesis. Eur Urol 39: 491-497
4. Dumaz N, Milne DM, Jardine LJ, Meek DW (2001) Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J 359: 459-464
5. Epstein JI, Amin MB, Reuter VR, Mostofi FK, the Bladder Consensus Conference Committee (1998) The World Health Organization/International Society of Urological Pathology Consensus Classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22: 1435-1448
6. Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Sölter JK, Huland E, Riethdorf L, Conrad S, Hammerer PG, Huland H (2001) Relevance of p53 gene alterations for tumour recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 39:159-166
7. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A (2000) Evaluation of p53 protein overexpression, Ki-67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38: 287-296
8. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC (2002) Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 161: 1119-1125
9. Murphy WM (1990) Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 21: 886-896
10. Olumi AF (2000) A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin N Am 27: 75-82
11. Piaton E, Daniel L, Verriele V, Dalifard I, Zimmermann U, Renaudin K, Gobet F, Caratero A, Desvaux D, Pouille Y, Seigneurin D, the urologists participating in the uCyt+ Trial (2003) Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest 83: 845-852
12. Piaton E, Faÿnel J, Ranchin MC, Hutin K (2002) Comparative study of conventional techniques and liquid-based processing of urine samples for the evaluation of bladder neoplasms (Abstract). Acta Cytol 46: 207
13. Piaton E, Faynel J, Ranchin MC, Hutin K, Cottier M (2004) Cost-efficiency analysis of modern cytocentrifugation methods versus liquid-based (Cytyc Thinprep*) processing of urinary samples. J Clin Pathol 57: 1208-1212
14. Prescott JL, Montie J, Pugh TW, McHugh T, Veltri RW (2001) Clinical sensitivity of p53 mutation detection in matched bladder tumour, bladder wash, and voided urine specimens. Cancer 91: 2127-2135
15. Righi E, Rossi RE, Ferrari G, Dotti A, De Gaetani C, Ferrari P, Trentini GP (1997) Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol 17: 436-439
16. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Woodman AC (2001) The early detection and diagnosis of bladder cancer: a critical review of the options. Eur Urol 39: 619-633
17. Sachs MD, Schlechte H, Lenk VS, Brenner S, Shnorr D, Fleige B, Ditscherlein G, Loening SA (2000) Genetic analysis of Tp53 from urine sediment as a tool for diagnosing recurrence and residual of bladder carcinoma. Eur Urol 38: 426-433
18. Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y (2000) p53 immunohistochemistry as a prognostic marker in bladder cancer. Eur Urol 38: 691-700
19. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B (1991) Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709
20. Sourvinos G, Kazanis I, Delakas D, Cranidis A, Spandidos DA (2001) Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumour suppressor genes. J Urol 165: 249-252
21. Stadler WM, Steinberg G, Ynag X, Hagos F, Turner C, Opolade OI (2001) Alterations of the 9p21 and 9q13 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 6: 1676-1682
22. Tisserand P, Fouquet C, Marck V, Mallard C, Fabre M, Vielh P, Soussi T (2003) Thinprep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis. Application to p53 mutation analysis. Cancer (Cancer Cytopathol) 99: 223-232
23. Wolf HK, Stöber C, Hohenfellner R, Leissner J (2001) Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 22: 328-336
24. Wright RG, Haiford JA (2001) Evaluation of thin-layer methods in urine cytology. Cytopathology 12: 306-313